Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.
A cancer patient receiving long-term oral sustained-release morphine treatment and periodically presenting with unusually high plasma M3G/M6G ratios is described. We found the patient's formation of M6G more unstable and perhaps delayed compared to the formation of M3G. There is no apparent explanation for this phenomenon and the high M3G/M6G ratios had no implications for the patient's pain experience or side effects from the morphine treatment.
Andersen
Gertrud
G
Multidiciplinary Pain Center, Herlev University Hospital, Herlev, Denmark
Christrup
Lona L
LL
Sjøgren
Per
P
Hansen
Steen Honoré
SH
Jensen
Niels-Henrik
NH
D000701:Analgesics, Opioid / Q000494:pharmacology* / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000097:blood* / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000494:pharmacology* / Q000627:therapeutic use*; D009022:Morphine Derivatives / Q000097:blood* / Q000494:pharmacology*; D010146:Pain / Q000097:blood / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000097:blood / Q000150:complications*; D013997:Time Factors
D000701:Analgesics, Opioid; D000697:Central Nervous System Stimulants; D009022:Morphine Derivatives; C035349:morphine-6-glucuronide; D009020:Morphine; C018108:morphine-3-glucuronide